DK3630726T3 - Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse - Google Patents

Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK3630726T3
DK3630726T3 DK18732548.5T DK18732548T DK3630726T3 DK 3630726 T3 DK3630726 T3 DK 3630726T3 DK 18732548 T DK18732548 T DK 18732548T DK 3630726 T3 DK3630726 T3 DK 3630726T3
Authority
DK
Denmark
Prior art keywords
crystallinic
dimethoxyquinolin
dicarboxamide
cyclopropane
fluorophenyl
Prior art date
Application number
DK18732548.5T
Other languages
Danish (da)
English (en)
Inventor
Khalid Shah
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62683441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3630726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of DK3630726T3 publication Critical patent/DK3630726T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DK18732548.5T 2017-05-26 2018-05-26 Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse DK3630726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511714P 2017-05-26 2017-05-26
PCT/US2018/034784 WO2018218233A1 (en) 2017-05-26 2018-05-26 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Publications (1)

Publication Number Publication Date
DK3630726T3 true DK3630726T3 (da) 2022-03-07

Family

ID=62683441

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18732548.5T DK3630726T3 (da) 2017-05-26 2018-05-26 Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse

Country Status (20)

Country Link
US (3) US11279675B2 (enExample)
EP (1) EP3630726B1 (enExample)
JP (3) JP7166292B2 (enExample)
KR (1) KR102611445B1 (enExample)
CN (1) CN110621662B (enExample)
AU (1) AU2018272088C1 (enExample)
CA (1) CA3060370A1 (enExample)
DK (1) DK3630726T3 (enExample)
EA (1) EA039654B1 (enExample)
ES (1) ES2909390T3 (enExample)
HU (1) HUE058196T2 (enExample)
IL (1) IL270780B2 (enExample)
MA (1) MA48776A (enExample)
MX (1) MX2019012505A (enExample)
PL (1) PL3630726T3 (enExample)
PT (1) PT3630726T (enExample)
SG (1) SG11201909161PA (enExample)
UA (1) UA127760C2 (enExample)
WO (1) WO2018218233A1 (enExample)
ZA (1) ZA201906127B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3738952A1 (en) * 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
WO2018218233A1 (en) * 2017-05-26 2018-11-29 Exelixis, Inc. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EP4647127A3 (en) 2018-01-26 2025-12-17 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN115569137A (zh) 2018-06-15 2023-01-06 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CR20210375A (es) 2018-12-13 2021-08-18 Exelixis Inc Formas cristalinas y formas de sal de un inhibidor de cinasa
AU2019449809A1 (en) * 2019-06-03 2021-12-16 Exelixis, Inc. Crystalline salt forms of a kinase inhibitor
JP2025506934A (ja) 2022-03-01 2025-03-13 シントン・ビー．ブイ． カボザンチニブのｌ－（＋）－酒石酸塩とその固体
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436888T3 (es) 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
EP2387563B2 (en) 2009-01-16 2022-04-27 Exelixis, Inc. Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
EP2621483A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
FI2621481T4 (fi) 2010-09-27 2023-01-13 Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
EP4019498A1 (en) 2011-02-10 2022-06-29 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
US20140179736A1 (en) 2011-05-02 2014-06-26 Exelixis, Inc. Method of Treating Cancer and Bone Cancer Pain
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
US9535315B2 (en) 2011-10-31 2017-01-03 Applied Materials, Inc. Method of fabricating a color filter array using a multilevel structure
JP2014532766A (ja) 2011-11-08 2014-12-08 エクセリクシス， インク． 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤
JP2015505360A (ja) 2011-11-08 2015-02-19 エクセリクシス， インク． 癌治療を定量化する方法
CN104649969B (zh) 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
EP3738952A1 (en) * 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US9815789B2 (en) * 2014-05-23 2017-11-14 Mylan Laboratories, Ltd. Polymorphs of cabozantinib (S)-malate and cabozantinib free base
CN104961680B (zh) 2014-11-07 2017-09-12 苏州晶云药物科技有限公司 N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN104961681B (zh) 2014-11-13 2017-06-13 苏州晶云药物科技有限公司 卡博替尼的粘酸盐及其晶型
US10206916B2 (en) * 2015-03-25 2019-02-19 Sandoz Ag Cabozantinib salts and their use as anti-cancer agents
EP3274332B1 (en) 2015-03-25 2018-12-19 Sandoz AG Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
CN109922790B (zh) * 2016-09-12 2022-06-14 珠海贝海生物技术有限公司 卡博替尼制剂
EP3551612A4 (en) * 2016-12-07 2020-08-12 MSN Laboratories Private Limited, R&D Center PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
WO2018218233A1 (en) 2017-05-26 2018-11-29 Exelixis, Inc. Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Also Published As

Publication number Publication date
IL270780B2 (en) 2025-04-01
CN110621662A (zh) 2019-12-27
AU2018272088A8 (en) 2019-10-24
JP7437460B2 (ja) 2024-02-22
EA201992803A1 (ru) 2020-04-16
US12227481B2 (en) 2025-02-18
EA039654B1 (ru) 2022-02-22
IL270780B1 (en) 2024-12-01
KR20200010205A (ko) 2020-01-30
IL270780A (en) 2020-01-30
HUE058196T2 (hu) 2022-07-28
US20240010621A1 (en) 2024-01-11
KR102611445B1 (ko) 2023-12-06
US11279675B2 (en) 2022-03-22
US20220162166A1 (en) 2022-05-26
EP3630726B1 (en) 2021-12-22
PL3630726T3 (pl) 2022-05-09
AU2018272088C1 (en) 2022-09-22
ES2909390T3 (es) 2022-05-06
CN110621662B (zh) 2023-06-23
SG11201909161PA (en) 2019-10-30
CA3060370A1 (en) 2018-11-29
NZ757564A (en) 2025-05-02
AU2018272088A1 (en) 2019-10-17
AU2018272088B2 (en) 2022-06-16
EP3630726A1 (en) 2020-04-08
JP2022145852A (ja) 2022-10-04
JP2020521732A (ja) 2020-07-27
US11731941B2 (en) 2023-08-22
WO2018218233A1 (en) 2018-11-29
UA127760C2 (uk) 2023-12-27
JP7659097B2 (ja) 2025-04-08
PT3630726T (pt) 2022-03-02
US20210261509A1 (en) 2021-08-26
JP2024036690A (ja) 2024-03-15
MA48776A (fr) 2020-04-08
JP7166292B2 (ja) 2022-11-07
ZA201906127B (en) 2022-11-30
MX2019012505A (es) 2019-12-19

Similar Documents

Publication Publication Date Title
DK3630726T3 (da) Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse
ZA201605424B (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
EA201591756A1 (ru) Метаболиты n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
SI3713919T1 (sl) Kristalinične oblike n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil) fenil)kinolin-8-sulfonamida
EA201891742A1 (ru) Замещенное пиперидиновое соединение и его применение
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
EP3536698A4 (en) LANOSTEROLPRODRUG COMPOUND AND MANUFACTURING METHOD THEREFOR AND USE THEREOF
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
EP3723752A4 (en) NEW SOLID FORMS OF CANNABIDIOL AND USES OF IT
EP3572409A4 (en) 1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EA201891644A1 (ru) Антибактериальные соединения и их применение
MA44672A (fr) Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3551612A4 (en) PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
EA201890570A1 (ru) [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
DK3752497T3 (da) P300/cbp-hat-hæmmere
EA201992259A1 (ru) Замещенные n-(1,3,4-оксадиазол-2-ил)арилкарбоксамиды и их применение в качестве гербицидов
EP3639845C0 (en) Il-15 protein complex pharmaceutical composition and uses thereof
EP3594216A4 (en) FIVE-PIECE HETEROCYCLIC AMINOPYRIMIDINE COMPOUND AND INTERMEDIATE PRODUCT, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
EP3419988A4 (en) NEW PRNA TRIPLE CONNECTIONS
MX386586B (es) Cristal de base libre de derivados benzofurano y método de preparación.
EA201990158A1 (ru) Производные бензодиоксана и их фармацевтическое применение
EA201991595A1 (ru) Активатор nrf2
BR112015011351A2 (pt) composição farmacêutica de difenidol de liberação sustentada